View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 11, 2017

Daiichi Sankyo, Max Planck and Lead Discovery form cancer research partnership

Daiichi Sankyo has signed a new agreement with Max Planck Innovation and Lead Discovery Center to form a new cancer research collaboration.

By Lopamudra Roy

Daiichi Sankyo has signed a new agreement with Max Planck Innovation and Lead Discovery Center to form a new cancer research collaboration.

As part of the partnership, Daiichi Sankyo will receive exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center.

The collaboration is built on biology insights in the field of transcriptional regulation from the work of professor Matthias Geyer at the Max Planck Institute of Molecular Physiology in Dortmund, Germany, and the Research Center caesar (Center of Advanced European Studies and Research) in Bonn, Germany.

Together with the Lead Discovery Center’s strong drug discovery expertise in the design of highly selective kinase inhibitors, the researchers from the three organisations will cooperate to further optimise the development of new compounds that target cancer cell transcription and proliferation.

"The three organisations will cooperate to further optimise the development of new compounds that target cancer cell transcription and proliferation."

Daiichi Sankyo Oncology Research and Development executive vice-president and global head Dr Antoine Yver said: “It is a great pleasure for us to start this research collaboration with Max Planck Innovation and the Lead Discovery Center to further generate innovation for our cancer drug discovery efforts."

Max Planck Society, supported by Max Planck Foundation, and Daiichi Sankyo will jointly fund the drug discovery efforts at the Lead Discovery Center.

Daiichi Sankyo also has the exclusive rights to licence the programme at pre-defined terms for subsequent preclinical and clinical development.

In the future, the three organisations aim to further enhance their partnership into additional drug development programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU